Calculate left ventricular mass index from echocardiographic measurements. Classifies LV hypertrophy severity and determines LV geometry pattern.
The LV Mass Index (LVMI) quantifies left ventricular hypertrophy by indexing LV mass to body surface area. Using the ASE-recommended Devereux formula, LV mass is calculated from three echocardiographic measurements: interventricular septal thickness (IVSd), LV internal diameter (LVIDd), and posterior wall thickness (PWTd), all measured at end-diastole.
LV hypertrophy is a major independent risk factor for cardiovascular morbidity and mortality, associated with increased risk of heart failure, arrhythmias, sudden cardiac death, and stroke. Importantly, LV hypertrophy is potentially reversible with blood pressure control, making serial LVMI measurement clinically valuable for monitoring treatment response.
Combining LVMI with relative wall thickness (RWT) enables classification into four LV geometry patterns: normal, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy — each with distinct clinical associations and prognostic implications. Check the example with realistic values before reporting. Use the steps shown to verify rounding and units. Cross-check this output using a known reference case. Use the example pattern when troubleshooting unexpected results.
LVMI provides objective, quantitative assessment of LV size for monitoring hypertensive heart disease, valvular heart disease, athletic heart, and hypertrophic cardiomyopathy. It is more reliable than qualitative visual assessment and enables serial comparison over time.
The geometry classification adds clinical value by distinguishing pressure-overload patterns (concentric) from volume-overload patterns (eccentric), guiding both diagnosis and treatment priorities.
LV Mass (Devereux/ASE) = 0.8 × 1.04 × [(IVSd + LVIDd + PWTd)³ − LVIDd³] + 0.6 LVMI = LV Mass / BSA (g/m²) Relative Wall Thickness (RWT) = 2 × PWTd / LVIDd BSA (DuBois) = 0.007184 × height^0.725 × weight^0.425
Result: LVMI 104 g/m² — Mildly Abnormal, Eccentric Hypertrophy
With IVSd 1.1, LVIDd 5.0, PWTd 1.0, and BSA 1.95 m², the LVMI of 104 g/m² is mildly elevated for a male (normal ≤95). RWT of 0.40 (≤0.42) with elevated LVMI indicates eccentric hypertrophy, suggesting volume overload as the likely etiology.
The Framingham Heart Study demonstrated that LV geometry, not just mass alone, predicts outcomes. Concentric hypertrophy carries the highest cardiovascular risk, followed by eccentric hypertrophy, concentric remodeling, and normal geometry. Each pattern has a distinct pathophysiology and treatment consideration.
BSA indexing is problematic in obesity because fat mass increases BSA without increasing cardiac demand proportional to lean body mass. Height-indexed LVMI (mass/height^2.7) eliminates this confound and is endorsed by ASE guidelines for obese patients. In extreme obesity, absolute LV mass without indexing may be most informative.
Cardiac MRI is the gold standard for LV mass quantification, with excellent accuracy and reproducibility. 3D echocardiography also improves accuracy over M-mode. Speckle tracking strain analysis provides additional information about myocardial mechanics beyond simple mass measurement.
BSA-indexed LVMI is the standard, but it underestimates LVH in obese patients because BSA increases with body weight. Height-indexed LVMI (mass/height^2.7) is preferred for obese patients as it better detects true hypertrophy. Cutoffs are 49.2 g/m^2.7 for men and 46.7 g/m^2.7 for women.
Yes. Blood pressure control, weight loss, and treatment of valvular disease can produce significant LVH regression. ACE inhibitors and ARBs appear to cause the most regression per mmHg blood pressure reduction. Regression of LVH is associated with reduced cardiovascular events independent of blood pressure levels.
Athlete’s heart typically shows mild eccentric hypertrophy (LVMI 95-115 in men) with normal diastolic function, a dilated LV cavity, and symmetric wall thickness. Red flags for pathological LVH: LVMI >130, RWT > 0.42, impaired relaxation, asymmetric hypertrophy, family history of sudden death, or abnormal ECG patterns.
Concentric hypertrophy (thick walls, normal cavity) results from pressure overload: chronic hypertension, aortic stenosis. Eccentric hypertrophy (normal walls, dilated cavity) results from volume overload: mitral/aortic regurgitation, obesity, high-output states. Concentric remodeling is an intermediate pattern often seen in early hypertension.
M-mode LV mass has reasonable reproducibility (coefficient of variation ~15-18%) in good-quality studies, but can be inaccurate with off-axis measurements, LV regional wall motion abnormalities, or asymmetric hypertrophy. 3D-echo and cardiac MRI provide more accurate LV mass measurement with lower variability.
The Sokolow-Lyon criteria (SV1 + RV5 or RV6 >35mm) and Cornell criteria (SV3 + RaVL >28mm men, >20mm women) are ECG markers of LVH, but their sensitivity is only 20-60%. ECG LVH with strain pattern (ST depression + T-wave inversion in lateral leads) carries worse prognosis than voltage-only criteria.